15,147 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 15,147 shares of the biotechnology company’s stock, valued at approximately $67,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. KBC Group NV boosted its position in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,198 shares in the last quarter. Journey Strategic Wealth LLC purchased a new stake in Ironwood Pharmaceuticals during the fourth quarter worth approximately $45,000. SG Americas Securities LLC purchased a new stake in Ironwood Pharmaceuticals during the fourth quarter worth approximately $53,000. CIBC Asset Management Inc acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $53,000. Finally, Wolverine Trading LLC purchased a new position in Ironwood Pharmaceuticals in the third quarter valued at approximately $51,000.

Ironwood Pharmaceuticals Stock Performance

Shares of Ironwood Pharmaceuticals stock opened at $1.54 on Thursday. The company has a market capitalization of $246.44 million, a P/E ratio of -51.33 and a beta of 0.37. Ironwood Pharmaceuticals, Inc. has a 1 year low of $1.43 and a 1 year high of $9.36. The company’s fifty day moving average is $2.97 and its two-hundred day moving average is $3.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company had revenue of $90.55 million during the quarter, compared to analyst estimates of $93.85 million. As a group, equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 192,381 shares of company stock valued at $338,591. 12.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

IRWD has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Craig Hallum decreased their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, JMP Securities cut their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.60.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.